These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8879382)

  • 1. Low-dose prednisone and increased risk of development of bone metastases.
    Body JJ
    Ann Oncol; 1996 Aug; 7(6):643. PubMed ID: 8879382
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors.
    Goodyear M
    J Clin Oncol; 1986 Mar; 4(3):442-4. PubMed ID: 3512787
    [No Abstract]   [Full Text] [Related]  

  • 3. Marked thrombocytosis after CMF chemotherapy.
    Bolzern U; Biasioli R; Rinaldi E; Negretti S
    Haematologica; 1989; 74(2):229. PubMed ID: 2501184
    [No Abstract]   [Full Text] [Related]  

  • 4. Higher average received relative dose intensities of cyclophosphamide, methotrexate and 5-fluorouracil using a 24-hour method: implications for improved cure rates in breast cancer.
    Price LA; Hill BT
    Cancer Treat Rev; 1990 Sep; 17(2-3):191-6. PubMed ID: 2272033
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of metastatic breast cancer].
    Yahalom J; Biran S; Sulkes A
    Harefuah; 1986 Jul; 111(1-2):8-11. PubMed ID: 2430868
    [No Abstract]   [Full Text] [Related]  

  • 6. High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer.
    Lamar RE; Greco FA; Johnson DH; Murphy PB; Hainsworth JD
    Cancer; 1994 Apr; 73(7):1842-8. PubMed ID: 8137208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
    Pinnamaneni K; Yap HY; Buzdar AU; Distefano A; Blumenschein GR
    Cancer; 1984 May; 53(9):1841-4. PubMed ID: 6546706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The problem of local control in patients with advance breast cancer--a combined modality approach.
    Boyages J
    Australas Radiol; 1986 Feb; 30(1):60-2. PubMed ID: 3755336
    [No Abstract]   [Full Text] [Related]  

  • 9. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.
    Falkson G; Gelman RS; Pandya KJ; Osborne CK; Tormey D; Cummings FJ; Sledge GW; Abeloff MD
    J Clin Oncol; 1998 May; 16(5):1669-76. PubMed ID: 9586877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer.
    Cadman EC; Glick JH; Cross J; Horton J; Taylor SG
    Cancer Treat Rep; 1984 Jun; 68(6):877-9. PubMed ID: 6547367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant therapy of breast cancer: a Southwest Oncology Group experience.
    Rivkin SE; Glucksberg H; Foulkes M
    Recent Results Cancer Res; 1984; 96():166-74. PubMed ID: 6396770
    [No Abstract]   [Full Text] [Related]  

  • 12. Adjuvant chemotherapy in breast cancer: back to the future.
    Colleoni M; Goldhirsch A
    Onkologie; 2003 Apr; 26(2):111-2. PubMed ID: 12771517
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of inoperable carcinoma of the breast by curative radiotherapy and chemo-hormonotherapy.
    Petera J; Filip S; Slampa P; Soumarová R; Coupek P; Zatloukal P
    Onkologie; 2001 Jun; 24(3):263-6. PubMed ID: 11455219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of advanced breast cancer with 2 successive chemotherapeutic schedules].
    Pérez JE; Machiavelli M; Romero A; Leone BA; Rabinovich MG; Arévalo E
    Medicina (B Aires); 1982; 42(6 Pt 1):587-95. PubMed ID: 6897849
    [No Abstract]   [Full Text] [Related]  

  • 15. An evaluation of the effect of vincristine added to cyclophosphamide, 5-fluorouracil, methotrexate, and prednisone in advanced breast cancer.
    Segaloff A; Hankey BF; Carter AC; Escher GC; Ansfield FJ; Talley RW
    Breast Cancer Res Treat; 1985; 5(3):311-9. PubMed ID: 3896353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose versus low-dose CMFP regimen in advanced breast cancer.
    Kumar A; Khanna NN; Pant GC; Khanna S
    J Surg Oncol; 1984 Apr; 25(4):300-2. PubMed ID: 6371385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Medroxyprogesterone acetate for treatment of advanced breast cancers].
    Mitsuyama S; Anan K
    Nihon Rinsho; 2000 Apr; 58 Suppl():317-21. PubMed ID: 11026012
    [No Abstract]   [Full Text] [Related]  

  • 18. Chemotherapy and concomitant irradiation in inflammatory breast cancer.
    Tubiana-Mathieu N; Lejeune C; Bonnier P; Genet D; Adjadj DJ; Berda JF; Muracciole X; Delaby F; Clavere P; Benyoub A; Rhein B; Juin B; Piana L
    Anticancer Res; 2001; 21(4B):3061-7. PubMed ID: 11712811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced breast cancer: How much chemotherapy is enough?
    DiPaola RS; Kaufman A; Mikhail MM
    Semin Oncol; 1996 Jun; 23(3):xv-xxii; discussion xxii-xxiv. PubMed ID: 8658211
    [No Abstract]   [Full Text] [Related]  

  • 20. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
    Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
    J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.